ReviewCancer communications (London, England)2025
Current status and perspectives of esophageal cancer: a comprehensive review.
Review in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Association between the HALP score and survival of patients with esophageal or gastro-esophageal junction cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- HPV prevalence in esophageal cancer: an updated systematic review and meta-analysis.Frontiers in microbiology · 2026Pooled it
- The effectiveness of intraoperative indocyanine green fluorescence imaging in preventing anastomotic leakage after minimally invasive esophagectomy for esophageal cancer: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in patients with esophageal cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Epigenetic silencingCancer biology & therapy · 2026Article
- Combined Impact of Sarcopenia and Low Visceral Adiposity on Postoperative Outcomes and Survival After Esophagectomy for Esophageal Cancer.Annals of surgical oncology · 2026Article
- LINC01446/miR-338-3p/APEX1 Axis Promotes Ferroptosis Defense and Progression in Esophageal Squamous Cell Carcinoma.Cancers · 2026Article
- Immunomodulatory effects of biodegradable Mg-Cu-Zn alloy in esophageal cancer.Bioactive materials · 2026Article
- Single-Cell and Bulk Transcriptomics Identify GNGT1-High Malignant Epithelial Cells Associated With Immune Suppression in Esophageal Squamous Cell Carcinoma.Chemical biology & drug design · 2026Article
- Global trends and hotspots in oxidative stress and esophageal cancer research: a comprehensive bibliometric and visualized analysis based on the Web of Science Core Collection (1998-2026).Journal of thoracic disease · 2026Article
- Garcinoic acid promotes ferroptosis-associated growth inhibition in esophageal squamous cell carcinoma through an MDM2-associated mechanism.Translational cancer research · 2026Article
- PVR Mediates Resistance to IL21.CD276.CAR-T Therapy in Esophageal Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Performance of DeepSeek V3 and ChatGPT-4o in answering esophageal cancer-related questions.Medicine · 2026Article
- Review
- A palmitoylation signature for prognosis immune infiltration and drug sensitivity in esophageal carcinoma.iScience · 2026Article
- Mitophagy interacts with mitochondrial dynamics and biogenesis, acting as a double-edged sword in digestive cancer.iScience · 2026Review
- An Integrated Circumferential Proportion and Defect Length Index for Predicting Esophageal Stricture After ESD in Large Mucosal Defects ≥6 cm.Journal of clinical medicine · 2026Article
- VAV2 drives glycolytic reprogramming in esophageal squamous cell carcinoma via EIF3F-mediated MTA1 deubiquitination.Cancer & metabolism · 2026Article
- XRN2, governed by RNA-binding protein PTBP3, promotes the invasiveness of esophageal squamous cell carcinoma.Clinical & experimental metastasis · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Esophageal cancer (EC) continues to be a significant global health concern, with two main subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Prevention and changes in etiology, improvements in early detection, and refinements in the treatment have led to remarkable progress in the outcomes of EC patients in the past two decades. This seminar provides an in-depth analysis of advances in the epidemiology, disease biology, screening, diagnosis, and treatment landscape of esophageal cancer, focusing on the ongoing debate surrounding multimodality therapy. Despite significant advancements, EC remains a deadly disease, underscoring the need for continued research into early detection methods, understanding the molecular mechanisms, and developing effective treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.